ResMed Inc. (RMD)

NYSE: RMD · Real-Time Price · USD

236.67

0.08 (0.03%)

At close: May 01, 2025, 12:07 PM

0.03% (1D)

Bid	236.55
Market Cap	34.7B
Revenue (ttm)	5.02B
Net Income (ttm)	1.31B
EPS (ttm)	8.92
PE Ratio (ttm)	26.53
Forward PE	22.59
Analyst	Hold

Ask	236.79
Volume	242,029
Avg. Volume (20D)	1,265,720.9
Open	235.53
Previous Close	236.59
Day's Range	233.87 - 238.81
52-Week Range	179.42 - 263.05
Beta	0.76

About RMD

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use i...

Sector Healthcare

IPO Date Jun 2, 1995

Employees 9,980

Stock Exchange NYSE

Ticker Symbol RMD

Website https://www.resmed.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for RMD stock is "Hold." The 12-month stock price forecast is $272, which is an increase of 14.93% from the latest price.

Stock Forecasts

Earnings Surprise

ResMed has released their quartely earnings on Apr 23, 2025:

Revenue of $1.29B exceeds estimates by $12M, with 7.94% YoY growth.

EPS of 2.37 exceeds estimates by 0.01, with 11.27% YoY growth.

Why Price Moved

6 days ago

+10.14%

ResMed shares are trading higher after the company... Unlock content with Pro Subscription

1 month ago

-3.3%

ResMed shares are trading lower after Stifel cut its price target on the stock from $250 to $240.

News

Just now · zacks.com

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

5 days ago · zacks.com

ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

5 days ago · zacks.com

Buy These 5 Low-Leverage Stocks to Counter Market Volatility

The crux of safe investment lies in choosing a company that is not burdened with debt. You can buy BILI, KINS, ENGIY, ASML and RMD.

1 week ago · benzinga.com

ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36.

6 days ago · zacks.com

ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market

RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

6 days ago · seekingalpha.com

ResMed: Cornering The Market In Sleep Solutions

ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, e...

1 week ago · seekingalpha.com

ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript

ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Offi...

1 week ago · zacks.com

Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street es...

1 week ago · zacks.com

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago.

1 week ago · reuters.com

ResMed slightly beats quarterly profit estimates on sleep devices demand

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Load More News